



Advances in Uveal Melanoma

Guest Editors:

Prof. Dr. Takami Sato

Department of Medical Oncology,
Sidney Kimmel Cancer Center,
Thomas Jefferson University,
1015 Walnut Street, 1024 Curtis
Building, Philadelphia, PA 19107,
USA

Dr. Mizue Terai

Department of Medical Oncology,
Sidney Kimmel Cancer Center,
Thomas Jefferson University,
1015 Walnut Street, 1015 Curtis
Building, Philadelphia, PA 19107,
USA

Deadline for manuscript
submissions:

30 April 2025

Message from the Guest Editors

Dear Colleagues,

Uveal melanoma (UM) is a rare form of melanoma, accounting for approximately 5% of all melanoma cases in the United States. Despite successful treatments of primary UM, up to 50% of UM patients subsequently develop systemic metastases, which spread predominantly to the liver.

Over the last decade, major discoveries have been made in the field of UM, including the identification of $G\alpha_q/11$ mutations as driver mutations and BAP1 and SF3B1 mutations as epigenetic determinants. Advances in technology also resulted in two treatments being approved by the US FDA, namely T-cell engager, tebentafusp-tebn (Kimmtrak™), and percutaneous hepatic perfusion with HEPZATO KIT™ (melphalan for injection/hepatic delivery system). These approaches totally changed the landscape of treatment for metastatic uveal melanoma (MUM).

In this Special Issue, we aim to envision the current status of our understanding of UM and discuss the future directions of translational research projects. We hope that this Special Issue will guide researchers in the field of UM to identify a curative approach for MUM patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)